FindTrial
Sign In

Safety and Effectiveness of Japanese Herbal Kampo Medicines for Treating Hyperemesis Gravidarum

Safety and Effectiveness of Japanese Herbal Kampo Medicines for Treating Hyperemesis Gravidarum - Safety and Effectiveness of Japanese Herbal Kampo Medicines for Treating Hyperemesis Gravidarum

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000032706
Enrollment
100000
Registered
2018-05-24
Start date
2018-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperemesis gravidarum

Interventions

None listed

Sponsors

The University of Tokyo
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: All mothers who were admitted to obstetric clinics or hospitals for delivery from January 2005 to December 2016 and on their newborns.

Exclusion criteria

Exclusion criteria: We excluded mothers aged under 19 years.

Design outcomes

Primary

MeasureTime frame
Safety outcomes included newborns' congenital anomalies, low birthweight (ICD-10, P070 or P071), and preterm birth (P072 or P073). Congenital anomalies were defined according to the criteria of the Congenital Anomaly Register for Oxfordshire, Berkshire and Buckinghamshire.—

Secondary

MeasureTime frame
For mothers with hyperemesis gravidarum, we defined effectiveness outcomes as unplanned hospital admission for treating hyperemesis gravidarum and total medical costs during pregnancy within 20 weeks of gestation.—

Countries

Japan

Contacts

Public ContactNobuaki Michihata

The University of Tokyo Department of Health Services Research, Graduate School of Medicine

michihata-tky@umin.org+81-3-5841-1887

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026